Celsion Corporation Announces ThermoDox® Abstract Accepted at the 2014 American Society of Clinical Oncology 50th Annual Meeting - KNOE 8 News; KNOE-TV; KNOE.com |

Celsion Corporation Announces ThermoDox® Abstract Accepted at the 2014 American Society of Clinical Oncology 50th Annual Meeting

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Celsion Corporation

Abstract Presents a Retrospective Analysis of the Company's 701 Patient HEAT Study and Compelling Data Showing Enhanced Efficacy When Radiofrequency Ablation is Combined with ThermoDox and When Heating Time of the RFA Procedure is Greater Than 45 Minutes

LAWRENCEVILLE, N.J., May 16, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that an abstract on its Phase III HEAT Study of ThermoDox, the Company's proprietary heat-activated liposomal encapsulation of doxorubicin, plus radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC) or primary liver cancer has been accepted for publication at the 2014 ASCO (American Society of Clinical Oncology) meeting in Chicago being held on May 30June 3, 2014. The abstract presents a retrospective analysis of the 701 patient HEAT Study and strong, consistent survival data supporting the continued development of ThermoDox in HCC.  Celsion will have an exhibit booth (24105) at the ASCO conference.

The abstract, titled "Standardized radiofrequency ablation (sRFA) > 45 minutes plus lyso-thermosensitive liposomal doxorubicin (LTLD) for solitary hepatocellular carcinoma (HCC) lesions 3-7 cm: A retrospective analysis of Phase III HEAT Study," is authored by many of the leading international research and clinical experts in primary liver cancer.

Dr. Nicholas Borys, Celsion's Chief Medical Officer commented, "The HEAT Study abstract selected for publication at ASCO 2014 serves as the basis for our upcoming 550 patient global Phase III OPTIMA Study in hepatocellular carcinoma.  This abstract summarizes what we see as compelling data developed from post hoc, multivariate Cox regression analysis. Both unvariate and multivariate analyses suggest that efficacy is considerably enhanced when radiofrequency ablation is combined with ThermoDox and when heating or dwell time of the RFA procedure is greater than 45 minutes.    We have worked closely with statisticians, regulators and leading experts in liver cancer to design our global Phase III OPTIMA Study, which we believe establishes a clear path to approval.  We are very proud of the strong participation and support of the authors in this study which include many leading international experts in liver cancer. "

In April 2014, Professor Riccardo Lencioni, MD, FSIR, EBIR, Professor and Director of Diagnostic Imaging and Intervention at the Pisa University School of Medicine, presented the latest overall survival data from the HEAT Study at the 5th European Conference on Interventional Oncology. As of March 31, 2014, data from the latest HEAT Study post-hoc analysis suggest that ThermoDox may markedly improve overall survival, compared to RFA control, in patients whose lesions undergo RFA treatment for 45 minutes or more.  These findings apply to patients with single HCC lesions (64.4% of the HEAT Study population) from both size cohorts of the HEAT study (3-5 cm and 5-7 cm) and represent a subgroup of 285 patients (41% of the patients in the HEAT Study).  For this large subgroup of patients, clinical results indicate a 50% improvement in overall survival, a hazard ratio of 0.666 (95% CI 0.434 - 1.022), and a p-Value of 0.06. The survival data emerging from our HEAT Study underscore the potential of ThermoDox in combination with an optimized radiofrequency ablation procedure.

In February 2014, Celsion announced that the U.S. Food and Drug Administration (FDA), following its customary 30 day review, allowed the Company's planned pivotal, double-blind, placebo-controlled Phase III OPTIMA Study.  The OPTIMA Study is expected to enroll 550 patients, with up to 100 sites in the United States, Europe, China and Asia Pacific and will evaluate ThermoDox in combination with RFA, which will be standardized to a minimum of 45 minutes across all investigators and sites for treating lesions 3 to 7 centimeters, versus standardized RFA alone. The primary endpoint for the trial is overall survival (OS).  The statistical plan calls for two interim efficacy analyses by an independent Data Monitoring Committee (iDMC).

About ThermoDox®

ThermoDox® is a proprietary heat-activated liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers.  ThermoDox® is being evaluated in a Phase III clinical trial for primary liver cancer and a Phase II clinical trial for recurrent chest wall breast cancer.  Localized mild hyperthermia (39.5 - 42 degrees Celsius) created by radiofrequency ablation (RFA) releases the entrapped doxorubicin from the liposome.  This delivery technology enables high concentrations of doxorubicin to be deposited preferentially in a targeted tumor. 

About Celsion Corporation

Celsion is dedicated to the development and commercialization of innovative cancer drugs, including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology.  Celsion has research, license or commercialization agreements with leading institutions, including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford.  For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.  Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the significant expense, time, and risk of failure of conducting clinical trials; HEAT Study data is subject to further verification and review by the HEAT Study Data Management Committee; the need for Celsion to evaluate its future development plans; termination of the Technology Development Contract or collaboration between Celsion and Hisun at any time; possible changes in cost and timing of development and testing, capital structure, financial condition, working capital needs and other financial items; possible acquisitions or licenses of other technologies, assets or businesses or the possible failure to make such acquisitions or licenses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion's periodic reports filed with the Securities and Exchange Commission.  Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor Contact

Jeffrey W. Church
Senior Vice President and
Chief Financial Officer
609-482-2455
jchurch@celsion.com

©2012 PR Newswire. All Rights Reserved.

  • Most Popular StoriesMost Popular StoriesMore>>

  • Union Sheriff: Man was attempting to hire hit man to kill family members

    Union Sheriff: Man was attempting to hire hit man to kill family members

    Monday, July 28 2014 1:21 PM EDT2014-07-28 17:21:58 GMT
    UNION PARISH, La. (KNOE 8 News UPSO) - A Ouachita Parish resident was arrested by Union Parish sheriff’s deputies and investigators over the weekend accused of solicitation of murder.
    UNION PARISH, La. (KNOE 8 News UPSO) - A Ouachita Parish resident was arrested by Union Parish sheriff’s deputies and investigators over the weekend accused of solicitation of murder.
  • K9 Officer helps nab Ruston robbery suspects

    K9 Officer helps nab Ruston robbery suspects

    Monday, July 28 2014 11:29 AM EDT2014-07-28 15:29:21 GMT
    RUSTON, La. (KNOE 8 News Ruston Police) - Two robbery suspects are in custody after leading several Ruston Police Officers and a K9 Officer on a chase through town.
    RUSTON, La. (KNOE 8 News Ruston Police) - Two robbery suspects are in custody after leading several Ruston Police Officers and a K9 Officer on a chase through town.
  • West Monroe man arrested for meth possession

    West Monroe man arrested for meth possession

    Sunday, July 27 2014 9:09 PM EDT2014-07-28 01:09:38 GMT
    WEST MONROE, La. (KNOE 8 News) - West Monroe Police arrested a man early Sunday morning for possession of drugs.
    WEST MONROE, La. (KNOE 8 News) - West Monroe Police arrested a man early Sunday morning for possession of drugs.
  • Homeowners don't want rehab built in their backyards

    Monday, July 28 2014 7:46 PM EDT2014-07-28 23:46:45 GMT
    MONROE, La. (KNOE 8 News) - Not in my back yard! That's what some homeowners in rural Ouachita Parish are saying about a rehab facility being built in their neighborhood. They've voiced their concerns to the Ouachita Parish Police Jury, but say they haven't gotten anywhere. 
    MONROE, La. (KNOE 8 News) - Not in my back yard! That's what some homeowners in rural Ouachita Parish are saying about a rehab facility being built in their neighborhood. They've voiced their concerns to the Ouachita Parish Police Jury, but say they haven't gotten anywhere. 
  • UPDATE: Missing elderly man has found his way back home

    UPDATE: Missing elderly man has found his way back home

    Monday, July 28 2014 3:06 PM EDT2014-07-28 19:06:27 GMT

    MONROE, La. (KNOE 8 News) - A missing elderly man in Monroe has found his way back home.

    MONROE, La. (KNOE 8 News) - A missing elderly man in Monroe has found his way back home.

  • Two arrests, officer tazed at Watermelon Festival

    Two arrests, officer tazed at Watermelon Festival

    Monday, July 28 2014 4:41 PM EDT2014-07-28 20:41:59 GMT
    FARMERVILLE, La. (KNOE 8 News UPSO) - Union Parish sheriff’s deputies made at least two arrests over the Watermelon Festival weekend, one that involved a deputy getting tazed.
    FARMERVILLE, La. (KNOE 8 News UPSO) - Union Parish sheriff’s deputies made at least two arrests over the Watermelon Festival weekend, one that involved a deputy getting tazed.
  • MPD investigate Friday night rape report

    MPD investigate Friday night rape report

    Saturday, July 26 2014 6:05 PM EDT2014-07-26 22:05:59 GMT
    MONROE, La. (KNOE 8 News) - Monroe Police are investigating a reported rape from Friday night.
    MONROE, La. (KNOE 8 News) - Monroe Police are investigating a reported rape from Friday night.
  • Retired deputy drowns trying to save terrier

    Retired deputy drowns trying to save terrier

    Sunday, July 27 2014 8:43 PM EDT2014-07-28 00:43:53 GMT
    Ret. Lt. Sam Vitter (Source: APSO)Ret. Lt. Sam Vitter (Source: APSO)
    PRAIRIEVILLE, La. (AP) - The Ascension Parish Sheriff's Office says a recently retired deputy has drowned trying to rescue his Yorkshire terrier.
    PRAIRIEVILLE, La. (AP) - The Ascension Parish Sheriff's Office says a recently retired deputy has drowned trying to rescue his Yorkshire terrier.
Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KNOE. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.